Table 3.
Osteoporosis Screening in Glucocorticoid Users
| Author | Study Period | Country | N | BMD Data Source | Mean Age, y | Female, % | Postmenopausal, % | Screened with BMD, % |
|---|---|---|---|---|---|---|---|---|
| Gudbjornsson45 | 1995 to 1996 | Iceland | 191 | MR | 66 | 55 | 76 | 1† |
| Solomon*46 | 1999 | U.S. | 236 | MR | 60 | 80 | 67 | 23 |
| Ettinger47 | 1998 to 1999 | U.S. | 8,807 | CD | N/A | 60 | N/A | 7 |
| Mudano*48 | 1995 to 1998 | U.S. | 6,821 | CD | 52 | 62 | N/A | 9 |
| Smith49 | 1999 | Australia | 189 | MR | 75 | 38 | 100 | 47 |
| Yood*50 | 1997 to 1998 | U.S. | 224 | CD | 70 | 57 | N/A | 31 |
| Osiri*51 | 1993 to 1999 | U.S. | 365 | MR | 53 | 59 | N/A | 19 |
| Buckley*52 | 1997 to 1998 | U.S. | 147 | SR | 51 | 58 | 50 | 29 |
All data adjusted.
Limited BMD equipment in geographic area studied.
MR, medical records; CD, claims data; SR, self-report; PM, postmenopausal.